ABO 1108
Alternative Names: ABO-1108Latest Information Update: 30 Jan 2026
At a glance
- Originator Suzhou Abogen Biosciences
- Class RNA vaccines; Varicella vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Herpes zoster
Most Recent Events
- 15 Nov 2025 Phase-II clinical trials in Herpes zoster (Prevention, In Adults, In the elderly) in China (Parenteral, Injection) (NCT07285278)